Peglion JL - Search Results

1

Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.

Pautus S, Alami M, Adam F, Bernadat G, Lawrence DA, De Carvalho A, Ferry G, Rupin A, Hamze A, Champy P, Bonneau N, Gloanec P, Peglion JL, Brion JD, Bianchini EP, Borgel D. Pautus S, et al. Among authors: peglion jl. Sci Rep. 2016 Nov 23;6:36462. doi: 10.1038/srep36462. Sci Rep. 2016. PMID: 27876785 Free PMC article.

2

Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: interaction studies with citalopram.

Gannon RL, Peglion JL, Millan MJ. Gannon RL, et al. Among authors: peglion jl. Eur Neuropsychopharmacol. 2009 Dec;19(12):887-97. doi: 10.1016/j.euroneuro.2009.06.011. Epub 2009 Jul 14. Eur Neuropsychopharmacol. 2009. PMID: 19604677

3

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.

Peglion JL, Poitevin C, Mannoury La Cour C, Dupuis D, Millan MJ. Peglion JL, et al. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2133-8. doi: 10.1016/j.bmcl.2009.03.015. Epub 2009 Mar 9. Bioorg Med Chem Lett. 2009. PMID: 19324548

4

Synthesis of benzocyclobutenes by palladium-catalyzed C-H activation of methyl groups: method and mechanistic study.

Chaumontet M, Piccardi R, Audic N, Hitce J, Peglion JL, Clot E, Baudoin O. Chaumontet M, et al. Among authors: peglion jl. J Am Chem Soc. 2008 Nov 12;130(45):15157-66. doi: 10.1021/ja805598s. Epub 2008 Oct 18. J Am Chem Soc. 2008. PMID: 18928284

5

Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity.

Thollon C, Bedut S, Villeneuve N, Cogé F, Piffard L, Guillaumin JP, Brunel-Jacquemin C, Chomarat P, Boutin JA, Peglion JL, Vilaine JP. Thollon C, et al. Among authors: peglion jl. Br J Pharmacol. 2007 Jan;150(1):37-46. doi: 10.1038/sj.bjp.0706940. Epub 2006 Nov 27. Br J Pharmacol. 2007. PMID: 17128289 Free PMC article.

6

Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.

Millan MJ, Iob L, Péglion JL, Dekeyne A. Millan MJ, et al. Among authors: peglion jl. Psychopharmacology (Berl). 2007 Apr;191(3):767-82. doi: 10.1007/s00213-006-0567-0. Epub 2006 Sep 19. Psychopharmacology (Berl). 2007. PMID: 17047933

7

The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.

Millan MJ, Gobert A, Roux S, Porsolt R, Meneses A, Carli M, Di Cara B, Jaffard R, Rivet JM, Lestage P, Mocaer E, Peglion JL, Dekeyne A. Millan MJ, et al. Among authors: peglion jl. J Pharmacol Exp Ther. 2004 Oct;311(1):190-203. doi: 10.1124/jpet.104.069625. Epub 2004 May 14. J Pharmacol Exp Ther. 2004. PMID: 15146031

8

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.

Millan MJ, Brocco M, Papp M, Serres F, La Rochelle CD, Sharp T, Peglion JL, Dekeyne A. Millan MJ, et al. Among authors: peglion jl. J Pharmacol Exp Ther. 2004 Jun;309(3):936-50. doi: 10.1124/jpet.103.062463. Epub 2004 Feb 20. J Pharmacol Exp Ther. 2004. PMID: 14978196 Free article.

9

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. Millan MJ, et al. Among authors: peglion jl. J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. doi: 10.1124/jpet.103.062414. Epub 2004 Feb 20. J Pharmacol Exp Ther. 2004. PMID: 14978195

10

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.

Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL. Millan MJ, et al. Among authors: peglion jl. J Pharmacol Exp Ther. 2004 Jun;309(3):903-20. doi: 10.1124/jpet.103.062398. Epub 2004 Feb 20. J Pharmacol Exp Ther. 2004. PMID: 14978194

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page